Since a significant portion of migratory subtype tumors exhibit EGFR gains, therapies targeting EGFR, such as tyrosine kinase inhibitors (TKIs) could be effective in this patient subset, as is currently being investigated for triple-negative breast cancer (TNBC) patients [44,45]. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.